Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

FBR & Co. (FBRC): Voce Capital Files a Definitive Proxy Statement

Page 1 of 9

Insider Monkey has reported recently about J. Daniel Plants Voce Capital  disappointment with the management of FBR & Co. (NASDAQ:FBRC) and its filing of a preliminary proxy requesting proxies to vote for its three nominees to the board, to vote against the non-binding advisory vote on named executive officer compensation and to approve the appointment of BDO USA, LLP as the FBR & Co.’s independent registered public accounting firm. And now, a newly-amended 13D filing with the US Securities and Exchange Commission has shown that Voce Capital has filed a definitive proxy statement in a Schedule 14A. Voce Capital, which owns 387,025 common shares that account for 5.2% of the total amount of the company’s outstanding stock, announced that it will continue to further actively follow actions made by the management and to propose new ideas with the objective to protect shareholders’ interests.

Follow Fbr & Co. (NASDAQ:FBRC)
Trade (NASDAQ:FBRC) Now!

FBR & Co. is an investment banking and institutional brokerage company that provides a plethora of investment services, such as capital raising and financial advisory, institutional brokerage and research, securities lending services to institutional investors, investments in merchant banking, to name a few. Year-to-date, FBR & Co.’s stock is down by 0.8%. For the first quarter of 2016, FBR & Co. reported a loss per share of $0.72, beating the estimates of a loss of $0.98 per share, and revenue of $17.9 million, versus estimates of $19.87 million. 

The number of hedge funds from our database supporting FBR & Co. (NASDAQ:FBRC) decreased to five during the fourth quarter, from six a quarter earlier. Voce Capital disclosed the most valuable position, followed by Chuck Royce’s Royce & Associates with a stake worth around $3.4 million. Other investors that were bullish on FBR & Co. (NASDAQ:FBRC) are D. E. Shaw’s D E Shaw, J. Alan Reid, Jr.’s Forward Management, and Paul Tudor Jones’s Tudor Investment Corp.

A hedge fund that lost interest in FBR & Co. and sold off its position is Israel Englander’s Millennium Management that dumped around $300,000 worth of shares between October and December.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Voce Capital Management 387,025 387,025 387,025 5.2%
Voce Capital 387,025 387,025 387,025 5.2%
J. Daniel Plants 387,025 387,025 387,025 5.2%

J. Daniel Plants
J. Daniel Plants
Voce Capital

Page 1 of 9 – SEC Filing

Washington, D.C.



§ 240.13d -2(a)
(Amendment No. 5)*

FBR & Co.
(Name of

Common Stock, $0.001 par value per share

(Title of Class of Securities)

(CUSIP Number)


600 Montgomery Street, Suite 210
San Francisco, California
(415) 489-2600
(Name, Address and Telephone
Number of Person Authorized to Receive Notices and Communications)

May 6, 2016
(Date of Event Which Requires
Filing of This Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule
13d-1(g), check the following box. [   ]

Follow Fbr & Co. (NASDAQ:FBRC)
Trade (NASDAQ:FBRC) Now!
Page 1 of 9

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!